Genzyme Molecular Oncology Begins Kidney Cancer Vaccine Trial

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 12
Volume 11
Issue 12

FRAMINGHAM, Massachusetts-Genzyme Molecular Oncology has launched a phase I/II vaccine trial in advanced kidney cancer. The vaccine is made by combining the patient’s own cancer cells with dendritic cells using an electrical fusion approach. Up to 20 patients will be enrolled at Beth Israel Deaconess Medical Center and the Dana-Farber Cancer Institute, Boston.

FRAMINGHAM, Massachusetts—Genzyme Molecular Oncology has launched a phase I/II vaccine trial in advanced kidney cancer. The vaccine is made by combining the patient’s own cancer cells with dendritic cells using an electrical fusion approach. Up to 20 patients will be enrolled at Beth Israel Deaconess Medical Center and the Dana-Farber Cancer Institute, Boston.

According to Genzyme, the cell fusion technology eliminates the need to identify specific tumor proteins because the technique uses the entire tumor cell to provide targets for the immune system to attack.

Articles in this issue
Tandem Transplants Increase CR, Reduce Treatment Mortality in Multiple Myeloma
Stereotactic Radiosurgery Benefits Brain Met Patients
Cancer Risk From Tainted Polio Vaccine Undetermined: IOM Report
Tailored Messages Motivate Women to Get Mammograms
Chemo/Rituximab Is Effective as First-Line CLL Therapy
Preoperative Capecitabine/RT Downstages Rectal Cancer
Intraoperative Lymphatic Mapping Enhances Cancer Staging
Rituximab Ups Survival in Aggressive and Indolent NHL
Genzyme Molecular Oncology Begins Kidney Cancer Vaccine Trial
Lower Breast Cancer Survival in Hispanics: New Mexico Study
Concurrent Chemo/RT More Likely to Save Larynx
Rituximab Improves Paclitaxel/ Topotecan Salvage Efficacy in NHL
CT Growth Assessment Reliably Diagnoses Solid Lung Nodules
Fludarabine Combos Showing Efficacy in Lymphomas
EntreMed’s Thalidomide Analog in Phase I Multiple Myeloma Trial

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Related Content
Time to deterioration in physical functioning and role functioning was similar among those receiving belzutifan vs everolimus for renal cell carcinoma.

Belzutifan Improves Disease-Specific Symptoms/QOL vs Everolimus in RCC

Roman Fabbricatore
April 6th 2025
Article

Time to deterioration in physical functioning and role functioning was similar among those receiving belzutifan vs everolimus for renal cell carcinoma.

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
April 1st 2025
Podcast

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

A World of Research, Care, and Science: Becoming A Radiation Oncologist

A World of Research, Care, and Science: Becoming A Radiation Oncologist

Tim Cortese
March 12th 2025
Article

James B. Yu, MD, MHS, FASTRO, didn’t always envision himself as a radiation oncologist, but now works tirelessly to treat patients and advance research for genitourinary cancers.

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO
March 7th 2025
Podcast

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.

Avelumab Combo Improves Long-Term Efficacy Vs Sunitinib in Advanced RCC

Russ Conroy
February 26th 2025
Article

Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.

Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

Top 5 Takeaways for Genitourinary Cancer Care From 2025 ASCO GU

Russ Conroy
February 21st 2025
Article

Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.